Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,otherCurrentLiab,netReceivables,depreciation,changeToLiabilities,changeToOperatingActivities,totalCashFromOperatingActivities,changeInCash,changeToNetincome,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,issuanceOfStock,changeToAccountReceivables,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 14, 2019) 4","Short Ratio (May 14, 2019) 4","Short % of Float (May 14, 2019) 4","Short % of Shares Outstanding (May 14, 2019) 4","Shares Short (prior month Apr 14, 2019) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,CYTR,7591657.0,36480000,,,-1279303,,-1279303,1276848,0,-1279848,-1279848,,,,,,0,0,1279848,0,545,,-1279303,-1279303,479561860.0,3029903.0,7591657.0,10621560.0,36480.0,-472006683.0,16836.0,9322529.0,2661813.0,571718.0,10033006.0,1218156.0,,,3303.0,-183898.0,779052.0,-680846.0,-680846.0,,,,,,,7371193.0,en-US,US,EQUITY,False,Delayed Quote,0.7396,1630436553,-0.00040000677,0.69,0.7599,0.69,47603,USD,PNK,26980608,-14400000,False,False,REGULAR,4,-0.054054968,0.69 - 0.7599,us_market,0,CYTRX CORP,0.71,0.0,0.0,11,10,finmb_265412,Other OTC,CytRx Corporation,USD,348470,102166,0.22960001,0.45019612,0.51 - 5.0,-4.2604,-0.85208,0.51,5.0,1509494400,1616675400,1616675400,1616675400,-0.192,-0.3,0.208,0.74277776,-0.003177762,-0.0042782137,1.9387681,-1.1991682,-0.6185207,-2.4653332,3.5557692,15,America/New_York,EDT,2.08,,,5.0,0.51,0.7428,1.9388,348.47k,102.17k,36.48M,,30.93M,15.21%,0.08%,294.31k,1.96,0.90%,0.87%,427.54k,,,,,,0.00%,"Oct 31, 2017",,1:6,"Oct 31, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.35%,-62.71%,,,,,-6.86M,-6.81M,-0.1920,,9.32M,0.26,552.42k,7.28,3.77,0.21,-5.23M,-3.35M,Value,90049,Healthcare,4,"CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.",Los Angeles,310 826 5648,CA,1609372800,United States,http://www.cytrx.com,86400,11726 San Vicente Boulevard,310 826 6139,Biotechnology,Suite 650
t-1,CYTR,8870960.0,36480000,-20373.0,,-1410972,,-1411772,1414115,0,-1422779,-1422779,,,,,,800,0,1422779,0,11807,,-1411772,-1411772,479561860.0,3189267.0,8870960.0,12060227.0,36480.0,-470727380.0,16836.0,10003375.0,2774067.0,620236.0,11423155.0,1402054.0,15568.0,325105.0,208616.0,-1445832.0,-16769.0,-2598502.0,-2598503.0,67255.0,,,,,,8649088.0,en-US,US,EQUITY,False,Delayed Quote,0.7396,1630436553,-0.00040000677,0.69,0.7599,0.69,47603,USD,PNK,26980608,-14400000,False,False,REGULAR,4,-0.054054968,0.69 - 0.7599,us_market,0,CYTRX CORP,0.71,0.0,0.0,11,10,finmb_265412,Other OTC,CytRx Corporation,USD,348470,102166,0.22960001,0.45019612,0.51 - 5.0,-4.2604,-0.85208,0.51,5.0,1509494400,1616675400,1616675400,1616675400,-0.192,-0.3,0.208,0.74277776,-0.003177762,-0.0042782137,1.9387681,-1.1991682,-0.6185207,-2.4653332,3.5557692,15,America/New_York,EDT,2.08,,,5.0,0.51,0.7428,1.9388,348.47k,102.17k,36.48M,,30.93M,15.21%,0.08%,294.31k,1.96,0.90%,0.87%,427.54k,,,,,,0.00%,"Oct 31, 2017",,1:6,"Oct 31, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.35%,-62.71%,,,,,-6.86M,-6.81M,-0.1920,,9.32M,0.26,552.42k,7.28,3.77,0.21,-5.23M,-3.35M,Value,90049,Healthcare,4,"CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.",Los Angeles,310 826 5648,CA,1609372800,United States,http://www.cytrx.com,86400,11726 San Vicente Boulevard,310 826 6139,Biotechnology,Suite 650
t-2,CYTR,10215478.0,36480000,592768.0,,-2774558,,-2774558,2207874,0,-2800642,-2800642,,,,,,0,0,2800642,0,26084,,-2774558,-2774558,479494604.0,5154002.0,10215478.0,15369480.0,36480.0,-469315606.0,16836.0,12601878.0,4689497.0,672572.0,14680072.0,3136376.0,,613905.0,7512.0,1570370.0,-909818.0,-2007151.0,-1985523.0,87278.0,-17373.0,39000.0,39000.0,12065.0,-17373.0,9990575.0,en-US,US,EQUITY,False,Delayed Quote,0.7396,1630436553,-0.00040000677,0.69,0.7599,0.69,47603,USD,PNK,26980608,-14400000,False,False,REGULAR,4,-0.054054968,0.69 - 0.7599,us_market,0,CYTRX CORP,0.71,0.0,0.0,11,10,finmb_265412,Other OTC,CytRx Corporation,USD,348470,102166,0.22960001,0.45019612,0.51 - 5.0,-4.2604,-0.85208,0.51,5.0,1509494400,1616675400,1616675400,1616675400,-0.192,-0.3,0.208,0.74277776,-0.003177762,-0.0042782137,1.9387681,-1.1991682,-0.6185207,-2.4653332,3.5557692,15,America/New_York,EDT,2.08,,,5.0,0.51,0.7428,1.9388,348.47k,102.17k,36.48M,,30.93M,15.21%,0.08%,294.31k,1.96,0.90%,0.87%,427.54k,,,,,,0.00%,"Oct 31, 2017",,1:6,"Oct 31, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.35%,-62.71%,,,,,-6.86M,-6.81M,-0.1920,,9.32M,0.26,552.42k,7.28,3.77,0.21,-5.23M,-3.35M,Value,90049,Healthcare,4,"CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.",Los Angeles,310 826 5648,CA,1609372800,United States,http://www.cytrx.com,86400,11726 San Vicente Boulevard,310 826 6139,Biotechnology,Suite 650
t-3,CYTR,12863757.0,36480000,592768.0,,-1341490,,-1341490,1379426,0,-1379426,-1379426,,,,,,0,0,1379426,0,37936,,-1341490,-1341490,479371170.0,2765325.0,12863757.0,15629082.0,33637.0,-466541050.0,19366.0,14587401.0,2258313.0,724449.0,14885267.0,952411.0,,12065.0,7512.0,69535.0,376953.0,-709494.0,-710041.0,86659.0,-548.0,39000.0,39000.0,91337.0,-548.0,12626954.0,en-US,US,EQUITY,False,Delayed Quote,0.7396,1630436553,-0.00040000677,0.69,0.7599,0.69,47603,USD,PNK,26980608,-14400000,False,False,REGULAR,4,-0.054054968,0.69 - 0.7599,us_market,0,CYTRX CORP,0.71,0.0,0.0,11,10,finmb_265412,Other OTC,CytRx Corporation,USD,348470,102166,0.22960001,0.45019612,0.51 - 5.0,-4.2604,-0.85208,0.51,5.0,1509494400,1616675400,1616675400,1616675400,-0.192,-0.3,0.208,0.74277776,-0.003177762,-0.0042782137,1.9387681,-1.1991682,-0.6185207,-2.4653332,3.5557692,15,America/New_York,EDT,2.08,,,5.0,0.51,0.7428,1.9388,348.47k,102.17k,36.48M,,30.93M,15.21%,0.08%,294.31k,1.96,0.90%,0.87%,427.54k,,,,,,0.00%,"Oct 31, 2017",,1:6,"Oct 31, 2017","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-31.35%,-62.71%,,,,,-6.86M,-6.81M,-0.1920,,9.32M,0.26,552.42k,7.28,3.77,0.21,-5.23M,-3.35M,Value,90049,Healthcare,4,"CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.",Los Angeles,310 826 5648,CA,1609372800,United States,http://www.cytrx.com,86400,11726 San Vicente Boulevard,310 826 6139,Biotechnology,Suite 650
